Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person spironolactone [cytosol]

Class:Id	ChemicalDrug:9725869
_displayName	spironolactone [cytosol]
_timestamp	2021-04-07 14:44:44
compartment	[Compartment:70101] cytosol
created	[InstanceEdit:9725834] Jassal, Bijay, 2021-04-01
disease	[Disease:9608426] hypertension [Disease:9608422] congestive heart failure [Disease:9726466] chronic kidney disease
literatureReference	[LiteratureReference:9726429] 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development [LiteratureReference:9725829] (S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor
modified	[InstanceEdit:9725889] Jassal, Bijay, 2021-04-01 [InstanceEdit:9726435] Jassal, Bijay, 2021-04-07
name	spironolactone Aldactone® spiractin spirotone
referenceEntity	[ReferenceTherapeutic:9725850] spironolactone [Guide to Pharmacology:2875]
stableIdentifier	[StableIdentifier:9725877] R-ALL-9725869.1
(hasMember)	[CandidateSet:9725842] NR3C2 antagonists [cytosol]
[Change default viewing format]

No pathways have been reviewed or authored by spironolactone [cytosol] (9725869)